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A B ST R AC T   
 
 
Neuroendocrine breast carcinomas represent a rare subtype of breast 
cancer. Their definition, prevalence and prognosis remain controversial 
in the literature. Regarding the presentation, there are no differences 
from other breast carcinomas and clinical syndromes related to hormone 
production are extremely rare. Refinement of the classification of 
neuroendocrine neoplasms of the breast is needed in order to improve 
the reproducibility of their diagnostic criteria and to define their clinical 
significance. 
This article presents the case of a 44-year-old female patient diagnosed 
with invasive breast carcinoma with neuroendocrine features, according 
to the 2012 World Health Organization (WHO) definition, with focus on 
presentation, clinical manifestations, diagnostic approach and 
differential diagnosis.   
 
Category: Case Presentation 
Received:  March 8, 2021 
Accepted:  July 19, 2021 
Published: October 10, 2021 
Keywords:  
invasive breast carcinoma, neuroendocrine, metastases, carcinoid 
syndrome 
*
Corresponding author:  
Iulia Gîvan, 
Niculaie Stăncioiu Heart Institute Cluj Napoca, Motilor Street 





Carcinomas with neuroendocrine differentiation 
represent <1% of breast carcinomas. However, since 
neuroendocrine markers are not routinely used on breast 
tumors with solid, alveolar and nested patterns of growth, 
the true incidence is difficult to assess [1]. 
Since primary mammary carcinoma with 
neuroendocrine features is rare, metastatic well-
differentiated neuroendocrine tumor (carcinoid) and poorly 
differentiated neuroendocrine carcinoma/small cell 
carcinoma should be excluded before making a final 
diagnosis [1]. Metastases of the breast account for less than 
1% of breast tumors and are most commonly hematologic 
or metastases from the contralateral breast. Metastatic 
neuroendocrine tumors account for 1-2% of breast 
metastases [2]. 
There are two main theories on the histogenesis of 
primary NETs of the breast. The first, a more controversial 
theory, affirms that these tumors evolve from the 
neoplastic transformation of native neuroendocrine cells. 
The second theory, which is more widely accepted, states 
that neuroendocrine differentiation arises from divergent 
differentiation of neoplastic stem cells into epithelial and 
endocrine cell lines during early carcinogenesis [2]. 
This paper presents the case of a young woman, 
diagnosed with invasive breast carcinoma with 
neuroendocrine features, who had no major risk factors and 
whose presentations were due to the presence of hepatic 
metastases. 
Case Presentation 
Patient H.F., aged 44 years, female, presented with the 
following complaints: pain in the right hypochondriac 
region, asthenia, unintentional weight loss (approximately 
13 kilos in four months), loss of appetite, nausea and 
vomiting (2-3 episodes/day). She was referred to our 
hospital by a regional hospital for further investigation and 
biopsy of some hepatic lesions seen on an abdominal and 
pelvic CT scans. At the CT scan, multiple hypodense 
lesions in both hepatic lobes were described. In contrast-
Neuroendocrine carcinoma of the breast: a case report 
 307 
enhanced CT, the lesions appear as rapidly enhancing 
lesions visible on the arterial phase. This enhancement 
pattern is characteristic to hypervascular metastases such 
as those from neuroendocrine tumors, renal cell carcinoma, 
breast carcinoma, melanoma and thyroid carcinoma. In the 
right lobe, the lesion had a maximum diameter of 176/111 
mm AP/LL, while, in the left lobe, the maximum diameter 
was up to 82 mm. There was also a small amount of ascites.   
She had a history of tobacco use, but she had quit 
smoking eleven years ago. The patient was also suffering 
from arterial hypertension, for which she was under 
treatment with angiotensin converting enzyme inhibitors 
and diuretics. There was no relevant family history. 
On the clinical examination, the patient was in a good 
general state, apyretic, with a blood pressure of 130/70 
mmHg, a pulse of 80 bpm, and a SpO2 of 98%. Lung and 
cardiac auscultation revealed no pathological aspects and 
the abdomen was insensitive to superficial and deep 
palpation. 
Laboratory investigation revealed: cholestasis with an 
elevated alkaline phosphatase (ALP) of 472 U/l (98-279), 
and a gamma-glutamyl transferase (GGT) of 305 U/l (7-
32), thrombocytosis PLT 486x10^3/ul (150-350), elevated 
erythrocyte sedimentation rate (ESR) 35 mm/1h (1-10). 
The transaminases were within normal limits, the surface 
antigen of the hepatitis B virus (HBsAg) was negative and 
the antibodies to the hepatitis C virus (anti-HCV 
antibodies) were also negative. 
The presence of hepatic lesions was confirmed by 
abdominal ultrasonography and a needle biopsy of the liver 
was performed. Based on the clinical presentation, 
ultrasound and CT scan images, the hepatic lesions were 
suspected to be metastases, most probably, of a 
neuroendocrine tumor. 
In anticipation of the histological results, investigations 
were conducted to search for a possible primary tumor. The 
upper endoscopy revealed acute erythematous pangastritis, 
while the lower endoscopy revealed grade II internal 
hemorrhoids, but no tumors. A thoracic CT scan was also 
performed, describing bone sclerotic lesions on the 
vertebral bodies (T6, T10, T11), sternum, scapula bilateral 
and the 6th left costal arch, and a mixed predominantly 
osteolytic bone lesion on the 7th right costal arch. Besides 
these bone lesions, a nodular densification in the right 
breast was also observed. 
A mammography (Figure 1) was performed, showing 
an irregular opacity with spiculiform contour in the supero-
external dial of the right breast. The maximum diameter of 
the lesion was 18/16 mm, and multiple microcalcifications 
(over 30) were observed. The next step was the ultrasound 
guided biopsy of the breast. At this moment, the possibility 
of having two different tumors at the same time was also 
included in the differential diagnosis.  
 
Figure 1. Mammography of the right breast: 
irregular opacity with spiculiform contour in the 
supero-external dial with a maximum diameter of 
18/16mm, and multiple microcalcifications. 
The histopathological exam of the breast biopsy 
(Figure 2), classified the breast lesion, according to the 
WHO definition in 2012, as an invasive breast carcinoma 
with neuroendocrine features. The coloration for neuron 
specific enolase (NSE) and synaptophysin were positive, 
while the cells were negative for chromogranin and CD56. 
Moreover, estrogen receptors (ER) were present in 100% 
of the tumor cells, while progesterone receptors (PR) were 
80% positive. The ki67 index of proliferation was 5%. The 
tumor was moderately differentiated, grade II Nottingham 
with a total score of six (tubule formation=3, nuclear 
pleomorphism=2, mitotic activity=1).  
 
Figure 2.  Breast biopsy. A. Hematoxylin and eosin 
(HE) staining x20. Tumor cells are disposed in nests and 
islands and no breast parenchyma is visible. The cells 
are small, without visible cell boundaries, the 
eosinophilic, fine granular cytoplasm is in small 
quantities; nuclei with granular chromatin, and no 
nucleolus visible; B. Immunohistochemical staining for 
neuron-specific enolase (NSE). Tumor cells are positive 
for NSE; C. Immunohistochemical staining for  
ER, x20. All tumor cells are ER-positive. D. 
Immunohistochemical staining for PR, x20.  80% of the 
tumor cells are PR-positive 
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The liver biopsy (Figure 3) confirmed the diagnosis by 
describing the aspect of metastases originating most 
probably from a mammary carcinoma. This was supported 
by the presence of ER in the liver biopsy.  Also, by 
comparing the breast biopsy (Figure 2A) and the liver 
biopsy (Figure 3A) in HE staining, it was observed that the 
tumor cells were similar. 
 
Figure 3. Liver biopsy – A) HE staining x20. A 
fragment of liver parenchyma with tumor proliferation 
formed by small and round cells with pale eosinophilic 
cytoplasm and round nuclei with granular chromatin 
and no nucleolus visible. The tumor cells are grouped 
in nests and islands and are visible in the lower part of 
the picture. B) Immunohistochemical staining for ER, 
x20. Tumor cells are ER positive. 
The final diagnosis was: Invasive breast carcinoma 
with neuroendocrine features with liver and bone 
metastases. Grade II hypertension with moderate to high 
risk. Acute erythematous pangastritis. Grade II internal 
hemorrhoids. The patient was referred to the oncologist. 
Discussions 
In this case, the patient was diagnosed with invasive 
breast carcinoma with neuroendocrine features, according 
to the WHO classification in 2012, based on the 
immunohistochemical staining for NSE and the aspect of 
tumor cells. The various definitions of this type of cancer 
are worth being discussed, as there are few articles on this 
topic, and the definitions have changed several times in the 
last years, and this may affect the way these studies are 
interpreted [3,4]. 
The lack of uniformity in the definition and 
classification of neuroendocrine carcinomas hampers an 
exact estimate of the prevalence of these tumors, ranging 
from 0.1% to 15% depending on the series. This may also 
explain the controversial data on the prognostic implication 
of neuroendocrine differentiation in breast cancer [3]. In 
2003, neuroendocrine carcinoma (NEC) of the breast was 
endorsed as a distinct entity in the third edition of the WHO 
Classification of Tumors series. Neuroendocrine tumors 
(NETs) of the breast were defined as tumors of epithelial 
origin, with morphology similar to that of gastrointestinal 
and pulmonary NETs, expressing neuroendocrine 
immunohistochemical markers (synaptophysin, 
chromogranin A) in at least 50% of the total invasive tumor 
cell population [4]. 
In 2012, in the fourth-edition volume WHO 
classification of tumors of the breast, NECs were included 
under the category “carcinomas with neuroendocrine 
features”, and they were defined as tumors exhibiting 
morphological features similar to those of the NETs of the 
gastrointestinal tract and of the lung, expressing 
neuroendocrine markers to any extent [4]. The revised 
2012 WHO classification includes three categories of 
NETs of the breast: (1) NETs well differentiated, which 
resembles carcinoid tumors and includes low and 
intermediate grade tumors; (2) NEC poorly differentiated 
(small cell carcinoma), which has the same features as a 
primary small cell carcinoma of the lung; (3) invasive 
breast carcinoma with neuroendocrine features, including 
no special type (NST), as well as special types such as solid 
papillary carcinoma and the hypercellular subtype of 
mucinous carcinoma [4-7]. 
Although the majority of the articles in the literature 
refer to the definition from 2012, it is important to mention 
that, in 2019, the International Agency for Research on 
Cancer (IARC) and the WHO adopted the term 
“neuroendocrine neoplasm (NEN)” as a term 
encompassing all tumor classes with predominant 
neuroendocrine differentiation, including both well-
differentiated and poorly differentiated forms. The 
morphology and the expression of the markers of 
neuroendocrine differentiation were recognized as the key 
features defining these neoplasms at any specific 
anatomical site. A uniform classification framework for 
NENs at all anatomical locations was proposed in order to 
reduce the inconsistencies and contradictions among the 
various systems currently in use [4-7]. 
Regarding the clinical presentation, neuroendocrine 
tumors of the breast occur predominately in white 
postmenopausal women in the sixth to seventh decade of 
life [2,5]. There are no notable or specific differences in 
presentation from other high-grade breast carcinomas and 
the clinical syndromes related to hormone production are 
extremely rare. Serological tests may detect circulating 
neuroendocrine markers such as chromogranin A [1,2]. 
"Carcinoid syndrome" is the term applied to a group of 
symptoms mediated by various humoral factors elaborated 
by some well-differentiated NETs which synthesize, store, 
and release a variety of polypeptides, biogenic amines, and 
prostaglandins. Carcinoid syndrome is most common in 
the setting of disseminated disease, particularly liver 
metastases, but it can occur in apparently locoregional 
disease [8]. The liver inactivates bioactive products 
secreted into the portal circulation. This may explain why 
patients with gastrointestinal NETs most often develop 
carcinoid syndrome if they suffer from hepatic metastases, 
resulting in the secretion of tumor products into the 
systemic circulation [9]. In the large majority of cases, 
carcinoid syndrome is associated with metastatic tumors 
originating in the midgut (jejunum, ileum, and cecum); 
however, the expression is variable in individual patients. 
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Less often, carcinoid syndrome is caused by a NET arising 
in the lung or in the distal colon or rectum and extremely 
rarely it is caused by NET arising in other sites such as the 
breasts. In table 1, the most important clinical 
manifestations of carcinoid syndrome are highlighted [10]. 
Table 1. Clinical manifestation of carcinoid syndrome  
1. Cutaneous flushing - the typical flush associated with 
midgut neuroendocrine tumors begins suddenly and 
lasts from 30 seconds to 30 minutes. It primarily 
involves the face, neck, and upper chest, which become 
red to violaceous or purple, and it is associated with a 
mild burning sensation.  
2.  Venous telangiectasia - appear late in the course of 
carcinoid syndrome. They are due to prolonged 
vasodilatation and most often occur on the nose, upper 
lip, and malar areas. 
3.  Secretory diarrhea - stools may vary from few to 
more than 30 per day, are typically watery and non-
bloody, and can be explosive and accompanied by 
abdominal cramping. Diarrhea is usually unrelated to 
flushing episodes. Transit time through the intestine 
may be extremely short. 
4. Bronchospasm - wheezing and dyspnea, often during 
flushing episodes. Carcinoid wheezing should not be 
confused with bronchial asthma because treatment with 
beta agonists can trigger intense, prolonged 
vasodilation. 
5. Cardiac valvular lesions - Carcinoid heart disease is 
characterized by pathognomonic plaque-like deposits of 
fibrous tissue. These deposits occur most commonly on 
the endocardium of valvular cusps, the cardiac 
chambers, and occasionally, the intima of the pulmonary 
arteries or aorta. The valves and the endocardium of the 
right side of the heart are most often affected because 
the inactivation of humoral substances by the lung 
protects the left heart. Left-sided valve disease may be 
caused by right-to-left shunting or with high levels of 
circulating vasoactive substances.  
In this case, the presentation was also not specific and 
was due mainly to pain in the right hypochondriac region, 
caused by the infiltration of the liver. What is notable in 
our case, is that the age of onset was 44 years and the 
menopause was not installed. 
The main risk factors for NEC of the breast are currently 
believed to be the same as for non-neuroendocrine breast 
cancer, such as age and family history. Moreover, the risk of 
the disease may also be increased by early menarche, late 
menopause as well as significant exposure to estrogen, 
typical of patients undergoing hormone replacement therapy 
or taking oral contraceptives [11]. Some evidence suggests 
a link between high prolactin level and breast cancer 
development; however, it is unclear whether breast NEC 
may be associated with hyperprolactinemia. Zang et al. 
have recently published two cases of breast NEC 
associated with hyperprolactinemia, one patient suffering 
from mental disorder under antipsychotic drugs, and 
another one diagnosed in late pregnancy [12]. 
As well as the clinical presentation, the radiologic 
characteristics are also unspecific and similar to the other 
malignant breast lesions. In a mini review article, Gallo et 
al. summarized the imaging characteristics of breast NEC, 
reported in case reports or small series: the most common 
mammographic appearance is a hyperdense, irregularly 
shaped solitary mass; margins are more commonly 
reported as indistinct, micro-lobulated or speculated. In 
most cases, calcifications are absent [12-14].  Taking into 
account the most common mammographic appearance 
described by Gallo et al., it is important to remember that 
multiple microcalcifications were observed in this case. 
There are no data from prospective clinical trials on the 
optimal management of NETs of the breast, and these 
tumors are usually treated with the same strategy used for 
other types of invasive breast carcinoma. Therefore, 
outside of the context of the exceedingly rare NEC of the 
breast, neuroendocrine differentiations in breast neoplasms 
are not regarded as specific therapeutic implications [4]. 
Surgery is the mainstay of the treatment for early NEC of 
the breast. Adjuvant radiation and systemic therapy must 
be decided in a personalizing view. Regimens including 
anthracyclines and/or taxanes are preferable when the 
indication for chemotherapy exists. Also, patients with 
positive hormone receptors are likely candidates for 
adjuvant endocrine therapy [15]. 
 Although breast NEC does not have a specific targeted 
therapy, several new targeted therapies based on specific 
biomarkers have recently been investigated in the NEC of 
the lung and in other types of breast carcinomas, which may 
provide guidance to their feasibility in breast NEC. 
According to an analysis performed by S.Vranic et al., 
several potential targets for novel therapies in breast NEC 
were identified, including farletuzumab and mirvetuximab 
soravtansine (FOLR1), sacituzumab govitecan (TROP-2), 
and HDAC inhibitors (H3K36Me3). For example, the 
expression of TROP-2 protein was found in 21% of the 
cases, suggesting that a small proportion of NEBCs may be 
sensitive to target therapy with sacituzumab govitecan. In 
some cases, CCND1 gene amplification may indicate the 
usefulness of investigational therapies [16,17]. All currently 
approved biomarkers of response to immune checkpoint 
inhibitors, have proven negative so far, thus suggesting that 
patients with neuroendocrine breast carcinoma are unlikely 
to benefit from immunotherapy [18]. The reported results 
should serve as an early indication of potential clinical 
relevance in selected patients with breast NEC.  
The tumor stage and the histological grade, which 
encompass mitotic counts, are used as the main prognostic 
 Iulia Gîvan et al.  
 310 
parameters. The prognostic relevance of neuroendocrine 
differentiation in breast carcinoma is still under debate, 
because of the lack of specific criteria for its definition; 
therefore, several studies have been published with mixed 
results [4]. These conflicting results might be explained by 
the different inclusion criteria based on whether 2003 or 
2012 WHO definitions were applied to identify NEC, by 
the limited number of cases reported in each series and also 
by the analysis performed considering NEC as a whole, 
without analyzing the outcomes according to the different 
histologic subtypes [19,20]. According to a study 
published by Yang et al., within the same clinical stage or 
grade, neuroendocrine tumors and neuroendocrine 
carcinoma of the breast had worse disease-specific survival 
(DSS) and overall survival (OS) than corresponding stage 
or grade of invasive ductal carcinomas of no special type 
(IDCs-NST). In univariate and multivariate survival 
analyses, NENs of the breast had significantly worse DSS 
and OS than IDCs-NST [21].  Even if this is a case of 
advanced breast carcinoma, with liver and bone metastases 
and a grade II Nottingham, the neuroendocrine component 
of the tumor made it difficult to make statements about the 
prognosis and the efficacy of the treatment. 
A limitation of this case report is the lack of 
information regarding the management of the case in the 
oncology department and the response to the treatment. As 
a strength point, this case report presents the discovery of 
a rare tumor, in a young patient without other important 
risk factors or comorbidities. It is worth mentioning that 
one of the challenges of this case was its management, both 
medically and with regard to the doctor-patient 
relationship, because of the necessity to provide 
information to the patient on a rare pathology whose 
treatment and prognosis are not well known. 
Conclusions 
Neuroendocrine tumors of the breast are rare and they 
can be misdiagnosed due to the lack of distinguishing 
features on presentation and imaging. Also, the expression 
of neuroendocrine markers is probably under-recognized 
in breast cancer, because routine staining of invasive breast 
carcinoma for neuroendocrine markers is not 
recommended, as there is currently no clinical relevance. 
Because of the low incidence of NEC, and because there 
are no data from prospective clinical trials, the optimal 
management and the prognosis should be derived from 
case reports or series. As future perspectives, cancer 
registries to centralize uniform data collection might be 
useful; moreover, prospective clinical trials are needed and 
better knowledge of the molecular profile could help to 
identify novel targets for a tailored treatment. The purpose 
of this case report is to raise awareness on this rare type of 
cancer and the lack of information regarding the prognosis 
and the optimal treatment.  
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